A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
Public ClinicalTrials.gov record NCT00389090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, phase II trial, assessing the antitumor activity, and safety of temozolomide in combination with O6-BG in patients with temozolomide-resistant anaplastic glioma.
Study identification
- NCT ID
- NCT00389090
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 32 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2006
- Primary completion
- May 31, 2008
- Completion
- Jan 31, 2009
- Last update posted
- Feb 8, 2012
2006 – 2009
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| AOI Pharmaceuticals Investigative Site | Los Angeles | California | 90033 | — |
| AOI Pharmaceuticals Investigative Site | Orlando | Florida | 32804 | — |
| AOI Pharmaceuticals Investigative Site | Chicago | Illinois | 60611 | — |
| AOI Pharmaceuticals Investigative Site | Evanston | Illinois | 60201 | — |
| AOI Pharmaceuticals Investigative Site | Lexington | Kentucky | 40536 | — |
| AOI Pharmaceuticals Investigative Site | Louisville | Kentucky | 40202 | — |
| AOI Pharmaceuticals Investigative Site | Minneapolis | Minnesota | 54407 | — |
| AOI Pharmaceuticals Investigative Site | Durham | North Carolina | 27710 | — |
| AOI Pharmaceuticals Investigative Site | Greenville | South Carolina | 29605 | — |
| AOI Pharmaceuticals Investigative Site | Dallas | Texas | 75246 | — |
| AOI Pharmaceuticals Investigative Site | Houston | Texas | 77024 | — |
| AOI Pharmaceuticals Investigative Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Glioma trials
Other public records listing Glioma. Sorted by last update posted; newest first. Not a recommendation.
- NCT07703436: Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease Not yet recruiting
- NCT07781852: Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer Not yet recruiting
- NCT07778979: Multiparametric Metabolic and Hypoxic PET/MRI Imaging Substudy in Gliomas Not yet recruiting
- NCT04186832: Step Count Monitoring as a Measure of Physical Activity in Patients With Newly Diagnosed Glioma Undergoing Radiation Therapy Active, not recruiting
- NCT05188508: Pembrolizumab, Olaparib, and Temozolomide for People With Glioma Recruiting
- NCT07488780: Language Network Prehab Via fMRI Neurofeedback Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00389090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 8, 2012 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00389090 live on ClinicalTrials.gov.